On September 22, 2015 Exelixis, Inc. (NASDAQ:EXEL) reported its slate of activities at the European Cancer Congress (ECC) 2015, which will be held September 25-29, 2015 in Vienna, Austria (Press release, Exelixis, SEP 22, 2015, View Source;p=RssLanding&cat=news&id=2089675 [SID:1234507516]). As previously announced, data from clinical trials of cabozantinib and cobimetinib will be the subject of three presentations at the meeting. The company will also host a live investor/analyst webcast on Saturday, September 26.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
METEOR Data to be Presented during the ECC 2015 Presidential Session I
As previously announced, detailed data from METEOR will be presented at the ECC as a late-breaking abstract in the Presidential Session I on Saturday, September 26, 2015. The details of the presentation are as follows:
• Abstract 4LBA: Late-Breaking Abstract: Cabozantinib versus Everolimus in Patients with Advanced Renal Cell Carcinoma: Results of the Randomized Phase 3 METEOR Trial
Toni K. Choueiri, M.D.
Presidential Session I
Saturday, September 26, 2015
Session from 14:30-16:40 CEST (8:30-10:40 a.m. EDT); presentation expected to begin at 16:20 CEST (10:20 a.m. EDT)